Rheumatoid Arthritis (RA) Drugs Markets 2016-2026

LONDON, August 1, 2016 /PRNewswire/ --

Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs and Other Agents) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets (US, Japan the EU5 and BRIC)

Rheumatoid Arthritis - New Study Showing You Those Drugs' Commercial Potentials
Where is the arthritic treatments market heading? Visiongain's updated report gives you forecasted revenues to 2026 for drugs treating rheumatoid arthritis (RA). There you find R&D trends, sales forecasting and commercial opportunities.

Our study lets you assess sales data and predictions for the world RA medicines market, therapeutic submarkets, products and national markets. Those analyses show you that pharmaceutical field's most promising and lucrative segments.

Read on to scan features of that industry, find what drives it, and see what its future market could be worth.

Forecasts and other analyses to help you assess the RA drugs market
Our report shows you revenue forecasts to 2026, sales results, growth rates and market shares. It lets you discover quantitative and qualitative analysis, business outlooks and R&D. Our 161 page report gives 67 tables and 65 charts to help your work.

With our study you can stay ahead in knowledge, benefiting your research, analyses, plans and decisions. There you find trends, innovations and opportunities for treating rheumatoid arthritis.

There is rising need worldwide for drugs treating arthritis. Our work helps you find markets, products and developments with most commercial promise.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

The following sections show how you benefit from our new study.

Discover sales predictions for that overall world market and submarkets
Along with revenue prediction for the overall world market for treating RA, our work shows you forecasts to 2026 for two main submarkets:
• Biologics (biological drugs, e.g. monoclonal antibodies [mAbs])
• Non-biologics (other therapeutic molecules).

For the non-biologics submarket, you get three further revenue breakdowns to 2026:
• NSAIDs
• sDMARDs
• Others agents (grouped).

From 2016, how will the RA drugs market expand? Which parts will most prosper? For anti-rheumatic medicines, our report helps you identify sales potentials and find opportunities.

Our investigation also discusses what stimulates and restrains business. There you explore dynamics of that industry, also seeing what products can achieve the most success.

See revenue forecasts for 11 leading drugs
Our study forecasts revenues of 11 leading products for rheumatoid arthritis, including the following drugs:
• Humira (adalimumab)
• Enbrel (etanercept)
• Remicade (infliximab)
• Rituxan (rituximab)
• Actemra (tocilizumab)
• Orencia (abatacept).

With our analysis you discover how high sales can go, to 2026, finding drugs and years with highest predicted revenues and growth. You also assess competition, exploring trends, challenges and opportunities.

Our analysis also divides its overall world RA revenue forecast into geographical segments.

What sales and growth potentials for leading countries?
In developed and developing countries - especially India and China - there remain many opportunities for expanded selling of drugs to treat rheumatoid arthritis. Our study shows you individual revenue forecasts to 2026 for eleven national markets:
• US
• Japan
• Germany, France, UK, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

That way you discover progress and outlooks. You assess the industry's future - hear about developments and find what they mean.

Our analysis shows revenue growth will occur in established pharma markets and in emerging countries. In particular, product launches from 2016 to 2026 will change anti-rheumatic drug prescribing and the commercial landscape. See what is possible.

Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new RA drugs? Our study shows you developmental trends for these agents and others:
• IL-6 inhibitors
• JAK inhibitors
• BTK inhibitors.

In our work you assess innovations, hearing about developments and finding their meaning. For large companies and specialty pharma firms there exist many opportunities in treating rheumatoid arthritis. Assess those firms' prospects.

Our study explains, also discussing forces affecting those companies and their market.

What affects the anti-arthritic drugs industry and market?
Our report discusses issues and events affecting that industry and market from 2016, including these developments:
• Biologics, including biosimilars
• Corticosteroids and other agents (e.g. JAK inhibitors)
• Demand for more-efficacious and better-tolerated drugs
• Need for less invasive routes of administration - drug delivery
• Biosimilars and generics as challengers to original-branded medicines
• Adalimumab, etanercept, infliximab and rituximab biosimilars
• Regional variability in biosimilar approval.

That way you explore technological, economic, social and political questions, assessing outlooks for that business.

Our investigation also lets you analyse the RA treatment industry's strengths, weaknesses, opportunities and threats. Discover what the future holds.

Leading companies and 2020 market value
What happens next? Our study predicts the overall world market for those anti-arthritic drugs will reach $34.6bn in 2020. From 2016 sales will rise.

Our analyses show you what products and organisations hold greatest potential, including these leading companies:
• AbbVie
• Roche
• J&J
• Amgen
• Pfizer
• Merck & Co.

Prospects for arthritic R&D are encouraging, and from 2016 there will arise opportunities, including product launches. Our work shows you technological, clinical and commercial possibilities, helping you stay ahead in knowledge.

6 main ways Rheumatoid Arthritis (RA) Drugs Market 2016-2026 helps your work
In particular our investigation gives you the following knowledge to help your research, plans, decisions and presentations:
• Revenues to 2026 for the overall rheumatoid arthritis drugs market and for 5 world-level submarkets - discover sales and growth potentials
• Revenues to 2026 for 11 leading products - find sales outlooks for top brands, seeing how they can compete and succeed
• Forecasts to 2026 for the US, Japan, Germany, France, UK, Spain, Italy, Brazil, Russia, India and China - see national sales potentials, finding the best regions for revenues and sales growth
• R&D for treating rheumatoid arthritis - investigate technologies and progress, assessing medical and commercial possibilities
• Discussions of leading companies, including profiles of 8 leading players - hear about strategies, capabilities, results and outlooks
• Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and gain advantages.

That investigation, by our in-house analysts in the UK, gives knowledge to benefit your work. Our study shows information you find nowhere else, helping you succeed.

Independent data to benefit your authority on treating rheumatoid arthritis
Our report gives you independent analysis. It shows competitive intelligence found only in our study, helping you assess technological and commercial potentials.

With that report you are less likely to fall behind in information or miss opportunity. Discover how you could benefit your analyses, plans and decisions, also saving time and helping your influence.

So explore the future of drugs treating rheumatoid arthritis. In our study you find data, trends, opportunities and sales predictions. Stay ahead by getting our new report here now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1699/Rheumatoid-Arthritis-(RA)-Drugs-Market-2016-2026

Companies Mentioned: 

   
    Abbott Laboratories
    AbbVie Inc
    Ablynx NV
    Agência Nacional de Vigilância Sanitária (ANVISA) Brazil
    Alder Biopharmaceuticals Inc
    American College of Rheumatology
    Amgen Inc
    Astellas Pharma Inc
    Baxalta
    Biocad
    Biocon Limited
    Biogen Inc
    BioXpress Therapeutics SA
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb (BMS)
    Can-Fite BioPharma Ltd
    Celltrion Inc
    Chugai Pharmaceutical Co Ltd
    Cipla Ltd
    Coherus BioSciences Inc
    Committee for Medicinal Products for Human Use (CHMP)
    Covagen AG
    Daiichi Sankyo Co Ltd
    Dr Reddy's Laboratories
    Drug Effectiveness Review Project, US
    Eli Lilly and Company
    European Medicines Agency (EMA)
    Epirus Biopharmaceuticals Inc
    European Commission
    F Hoffman-La Roche AG (Roche)
    Food and Drug Administration (FDA)
    Fujifilm Corporation
    Galapagos NV
    Genentech Inc
    Gilead Sciences Inc
    GlaxoSmithKline PLC (GSK)
    Hanmi Pharmaceutical Co Ltd
    Hanwha Biologics
    Hanwha Chemical Corp
    Hetero Healthcare Ltd
    Incyte Corporation
    Institut fϋr Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG),
    Germany
    Institute for Clinical and Economic Review, US
    Intas Pharmaceuticals Ltd
    Janssen Biologics BV
    Janssen Biotech Inc
    Janssen Pharmaceutical Companies
    Johnson & Johnson (J&J)
    Kyowa Hakko Kirin Co Ltd
    LG Life Sciences Ltd
    Merck & Co Inc
    Merck KGaA
    Merck, Sharp & Dohme Corp (MSD)
    Ministry of Food and Drug Safety, South Korea
    Ministry of Health, Italy
    Ministry of Health, Labor and Welfare (MHLW), Japan
    Mitsubishi Tanabe Pharma Corporation
    Momenta Pharmaceuticals Inc
    MorphoSys AG
    Mycenax Biotech Inc
    Mylan NV
    National Health Service (NHS), UK
    National Institute for Health and Care Excellence (NICE), UK
    National Institute for Health Research (NIHR), UK
    Nichi-Iko Pharmaceutical Co Ltd
    Novartis International AG
    Oncobiologics Inc
    Pfizer Inc
    Protalix Biotherapeutics
    Regeneron Pharmaceuticals Inc
    Samsung Bioepis Co Ltd
    Samsung BioLogics
    Sandoz
    Sanofi SA
    Servizio Sanitario Nazionale (SSN) Italy
    Shanghai Celgen Bio-Pharmaceutical Co Ltd
    Shanghai CP Guojian Pharmaceutical Co Ltd
    Simcere Pharmaceutical Group
    Sistema Único de Saúde (SUS) Brazil
    Sun Pharmaceutical Industries Ltd
    Takeda Pharmaceutical Co Ltd
    TSH Biopharm Corporation Ltd
    UCB SA
    US Patent Office
    Vitaeris Inc
    World Bank
    World Health Organisation (WHO)
    Zydus Cadila

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

SOURCE Visiongain Ltd